Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation-Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation
- PMID: 39853845
- DOI: 10.1111/jce.16573
Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation-Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation
Abstract
Background: Pulsed field ablation (PFA) is gaining recognition as a nonthermal, tissue-specific technique for the treatment of atrial fibrillation (AF). The preclinical evaluation of the investigated novel PFA system from Insight Medtech Co. Ltd has demonstrated feasibility, safety, and 30-day efficacy for pulmonary vein isolation (PVI) in the swine model. We are currently conducting a randomized controlled trial to compare the PFA directly with ablation-index (AI)-guided radiofrequency ablation (RFA) for PVI.
Methods and results: The InsightPFA trial is a prospective, multicenter, randomized controlled trial to compare the effectiveness and safety of PFA versus RFA for PVI in Chinese patients with symptomatic paroxysmal AF. Two hundred and ninety-two patients diagnosed with symptomatic paroxysmal AF will be randomly assigned to either the PFA group or the RFA group in a 1:1 ratio. All subjects will undergo PVI using PFA or AI-guided RFA and be followed up to 12 months. The primary endpoint is defined as freedom from any episodes of AF/AFL/AT without Class I or III antiarrhythmic drugs during the 9-month follow-up period after a 90-day blank period. The secondary endpoints of effectiveness include acute treatment success and procedural data. The safety evaluation includes a composite of death, stroke and transient ischemic attack, procedure-related complications, device-related adverse events, and serious adverse events. A noninferiority comparison will be conducted between the novel PFA system and the existing RFA system in terms of both effectiveness and safety.
Conclusions: This trial aims to determine whether the InsightPFA for PVI is as effective and safe as standard RFA in the treatment of symptomatic paroxysmal AF.
Trial registration: https://www.
Clinicaltrials: gov/study/NCT06014996; NCT06014996.
Keywords: atrial fibrillation; catheter ablation; pulmonary vein isolation; pulsed field ablation; randomized controlled trial.
© 2025 Wiley Periodicals LLC.
References
-
- S. Tzeis, E. P. Gerstenfeld, J. Kalman, et al., “2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation,” Europace 26 (2024): euae043.
-
- K.‐H. Kuck, J. Brugada, A. Fürnkranz, et al., “Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation,” New England Journal of Medicine 374 (2016): 2235–2245.
-
- L. Urbanek, S. Bordignon, D. Schaack, et al., “Pulsed Field Versus Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation: Efficacy, Safety, and Long‐Term Follow‐Up in a 400‐Patient Cohort,” Circulation: Arrhythmia and Electrophysiology 16 (2023): 389–398.
-
- V. J. H. M. van Driel, K. G. E. J. Neven, H. van Wessel, et al., “Pulmonary Vein Stenosis After Catheter Ablation: Electroporation Versus Radiofrequency,” Circulation: Arrhythmia and Electrophysiology 7 (2014): 734–738.
-
- K. Kuroki, W. Whang, C. Eggert, et al., “Ostial Dimensional Changes After Pulmonary Vein Isolation: Pulsed Field Ablation vs Radiofrequency Ablation,” Heart Rhythm: The Official Journal of the Heart Rhythm Society 17 (2020): 1528–1535.
Publication types
MeSH terms
Supplementary concepts
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
